Table 1. Clinical data of patients with... | American Society of Hematology

Table 1.

Clinical data of patients with cGVHD and the ratio of OX40⁺ T cells among total CD4 or CD8 T cells

UPN	aGVHD	cGVHD
UPN	Grade	Onset (mo after SCT)	Affected organ	Therapeutic response for primary therapy^†	OX40⁺CD4⁺^*	OX40⁺CD8⁺^*
1	IV	Progressive (5)	Skin, liver	Worsened	66%	58%
2	II	Quiescent (22)	Myasthenia gravis	Unchanged	47%	9%
3	III	Quiescent (3)	Stomach	Unchanged	60%	43%
4	III	Progressive (4)	Skin, liver, stomach	Unchanged	40%	13%
5	III	Progressive (3)	Skin, liver	Unchanged	87%	97%
6	I	Quiescent (14)	Liver, skin	Improved	43%	23%
7	II	Quiescent (8)	Lung, skin	Improved	22%	26%
8	I	Quiescent (4)	Liver	Improved	31%	24%
9	I	Quiescent (4)	Skin, liver	Improved	49%	37%
10	III	Quiescent (4)	Lung, liver	Improved	37%	40%
11	III	Quiescent (3)	Liver	Improved	39%	18%

UPN	aGVHD	cGVHD
UPN	Grade	Onset (mo after SCT)	Affected organ	Therapeutic response for primary therapy^†	OX40⁺CD4⁺^*	OX40⁺CD8⁺^*
1	IV	Progressive (5)	Skin, liver	Worsened	66%	58%
2	II	Quiescent (22)	Myasthenia gravis	Unchanged	47%	9%
3	III	Quiescent (3)	Stomach	Unchanged	60%	43%
4	III	Progressive (4)	Skin, liver, stomach	Unchanged	40%	13%
5	III	Progressive (3)	Skin, liver	Unchanged	87%	97%
6	I	Quiescent (14)	Liver, skin	Improved	43%	23%
7	II	Quiescent (8)	Lung, skin	Improved	22%	26%
8	I	Quiescent (4)	Liver	Improved	31%	24%
9	I	Quiescent (4)	Skin, liver	Improved	49%	37%
10	III	Quiescent (4)	Lung, liver	Improved	37%	40%
11	III	Quiescent (3)	Liver	Improved	39%	18%

cGVHD, chronic graft-versus-host disease; aGVHD, acute graft-versus-host disease; SCT, stem cell transplantation.

Data just before the beginning of intensive immunosuppressive therapy for cGVHD.

Primary therapy for cGVHD was increasing of tacrolimus or cyclosporin or beginning of prednisone.